Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.
Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 53, 44, 5, 21, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 4, 3, 3 and 1 molecules, respectively.
Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: Glenmark Specialty S.A. receives approval for conducting phase 1 clinical trial of its novel molecule GRC 54276 in patients with advanced solid tumors and Hodgkin's lymphoma
Apr 10, 2022: Affimed presents updated clinical data from phase 1/2 study of AFM13 precomplexed with cord blood-derived NK cells at AACR Annual Meeting
Dec 14, 2021: Tessa Therapeutics announces positive data from phase 2 trial of autologous CD30-CAR-T therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting
Dec 12, 2021: Seagen announces preliminary results from phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in novel combination of agents for patients with advanced stage classical hodgkin lymphoma
Dec 09, 2021: Affimed to host virtual investor call today to discuss treatment of CD30-positive lymphoma patients with cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13
Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications
Dec 02, 2021: Innovent and Lilly announce successful expansion of Sintilimab in China National Reimbursement Drug List to include three additional first-line indications
Nov 04, 2021: Seagen to highlight multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting
Nov 03, 2021: Tessa Therapeutics announces presentation of autologous cell therapy data at 2021 ASH Annual Meeting
Sep 27, 2021: ONO receives approval of Opdivo (nivolumab) for dosage and administration for treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan
Aug 30, 2021: Ligand's partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin's lymphoma
Jun 22, 2021: ADC Therapeutics announces encouraging interim results from pivotal phase 2 clinical trial of Camidanlumab Tesirine (Cami) presented at the 16th Annual International Conference on Malignant Lymphoma
Jun 09, 2021: ADC Therapeutics announces presentation on Camidanlumab at the 16th Annual International Conference on Malignant Lymphoma
May 26, 2021: ADC Therapeutics announces online publication of Camidanlumab Tesirine phase 1 results in The Lancet Haematology
May 14, 2021: Tessa Therapeutics announces positive, topline data from ongoing phase 1 trial of allogeneic, "Off-the-Shelf" cell therapy, in patients with relapsed or refractory CD30-positive lymphoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics SA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Adlai Nortye Biopharma Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Alfasigma SpA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Angiocrine Bioscience Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Apollomics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Astellas Pharma Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AstraZeneca Plc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Aurigene Discovery Technologies Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Avipep Pty Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bayer AG, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by BeiGene Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bio-Path Holdings Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Co, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Carrick Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Catalent Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectar Biosciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectis SA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celleron Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellestia Biotech AG, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celularity Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Checkmate Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Checkpoint Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Chimeric Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by CSL Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Daiichi Sankyo Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Dyadic International Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Eutilex Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Genentech USA Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gibson Oncology LLC, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gilead Sciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Helocyte Biosciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by HRAIN Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hutchison MediPharma Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Immune Cell Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corp, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Inhibrx Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Innovent Biologics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Intellia Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Kymera Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by LegoChem Biosciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Luye Pharma Group Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Magenta Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Marker Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by MediSix Therapeutics Pte Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Miltenyi Biotec BV & Co KG, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NewBio Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Northlake International LLC, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by OncoTartis Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by PlantForm Corp, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Protheragen Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rafael Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by RAPT Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rhizen Pharmaceuticals SA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sanofi, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seagen Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shattuck Labs Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by SpecificiT Pharma Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Syndax Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tacitus Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tessa Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tevogen Bio Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tubulis GmbH, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tyme Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Vincerx Pharma Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Viracta Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Waterstone Hanxbio Pty Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Xencor Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Global Cancer Immunomodulator Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 95
The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 125
According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
Published: 27-Dec-2023 Price: US 3350 Onwards Pages: 112
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Cancer Gene Therapy market:
According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
Published: 25-Dec-2023 Price: US 3350 Onwards Pages: 85
CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
Global Kaposi Sarcoma Market Status and Outlook 2023-2028
Published: 22-Dec-2023 Price: US 3160 Onwards Pages: 107
Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 21-Dec-2023 Price: US 3380 Onwards Pages: 118
Market Overview of Global Cancer Immunomodulator market:
According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
